Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Genentech BO29562: A Phase Ib/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma
Brief Description  
Objectives and Outcome Measures This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of induction treatment consisting of atezolizumab in combination with obinutuzumab plus lenalidomide (Atezo +G+ Len) in patients with relapsed or refractory follicular lymphoma (FL), followed by maintenance treatment with Atezo +G+ Len in patients who achieve a complete response (CR), a partial response (PR), or stable disease at end of induction (EOI). Specific objectives and cor
Who may be Eligible  
Please contact us for eligibility criteria.
Non-Hodgkin's Lymphoma
Start Date  
IRB Number  
Principal Investigator  
Ghosh, Nilanjan
Contact Name  
Donna Acampora

For More Information, Contact  Donna  , Acampora
Phone:  980-442-2319 Fax:    
Email:  Donna.Acampora@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204